Mazdutide

Plain-English version: Mazdutide is a lab-made peptide (a small protein) given as a once-a-week shot under the skin. It's built to help people with obesity or type 2 diabetes lose weight and improve their blood sugar. What makes it different from the drugs most people have heard of is that it hits two targets at once instead of one.

Those two targets are receptors — docking stations on your cells:

• The GLP-1 receptor: this is the same target as semaglutide (Ozempic/Wegovy). Activating it curbs appetite, helps the pancreas release insulin when blood sugar is high, and slows how fast the stomach empties — so you feel full longer.
• The glucagon receptor: this is the newer, second target. Glucagon is best known for raising blood sugar, but controlled activation of its receptor also tells the liver to burn stored fat and nudges the body to spend slightly more energy at rest.

The design bet is that combining "eat less" (GLP-1) with "burn more" (glucagon) produces more total weight loss than a GLP-1 drug alone, while the GLP-1 side keeps the glucagon side from pushing blood sugar up. Mazdutide is the first drug in this GLP-1/glucagon "dual agonist" class to win regulatory approval anywhere in the world.^[1][6]

Who made it and where it stands: Mazdutide was co-developed by Eli Lilly and the Chinese biotech Innovent Biologics, with the clinical program run mainly by Innovent in China. On June 27, 2025, China's National Medical Products Administration (NMPA) approved it for chronic weight management in adults with overweight or obesity — the world's first approval of a dual glucagon/GLP-1 receptor agonist for weight loss. The approved doses are 4 mg and 6 mg, and a higher 9 mg application (based on the GLORY-2 trial) was subsequently accepted for review.^[6]

The credibility caveat, stated up front: mazdutide is not FDA-approved in the United States, and US development is at an earlier stage than the Chinese program. Every published pivotal efficacy trial was conducted in Chinese populations; no non-Chinese pivotal trial has been published, and there is no long-term cardiovascular outcomes trial (the kind SELECT provided for semaglutide) yet. Just as important: mazdutide sold in US "research peptide" markets is unregulated and is not the clinical-grade molecule used in the Innovent/Lilly trials. For the legal picture, see Are Peptides Legal?

Takeaway first: Mazdutide is a single molecule that switches on two receptors. The GLP-1 side reduces how much you eat; the glucagon side increases how much energy you burn and helps clear fat out of the liver. Working together, they attack body weight from both ends — intake and expenditure.^[3]

1. GLP-1 receptor activation — the "eat less" engine

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after a meal. Mazdutide mimics it. Activating the GLP-1 receptor does three well-established things: it signals the appetite centers in the brain (the hypothalamus) to reduce hunger, it triggers glucose-dependent insulin release (meaning insulin goes up mainly when blood sugar is high, which limits hypoglycemia risk), and it slows gastric emptying so food stays in the stomach longer and you feel full. This is the same mechanism that made semaglutide and tirzepatide effective.^[3]

2. Glucagon receptor activation — the "burn more" engine

This is what sets mazdutide apart from GLP-1-only drugs. Glucagon's receptor, when activated in this controlled, GLP-1-balanced context, promotes hepatic fat oxidation — the liver burns its own stored fat — and modestly increases resting energy expenditure. That's why the compound is of particular interest for fatty-liver disease (MASH/MASLD), where excess liver fat is the core problem and pure GLP-1 drugs have a more limited direct effect. On its own, glucagon can raise blood sugar; but the simultaneous GLP-1 activity keeps glucose in check, which is the whole rationale for combining the two in one molecule.^[3][5]

3. Why "dual" instead of "single"

The net effect is weight loss driven by two independent levers at once: fewer calories in (GLP-1 appetite suppression and slowed digestion) and slightly more calories out (glucagon-driven energy expenditure and fat mobilization). In head-to-head class terms, this is a different strategy than tirzepatide, which pairs GLP-1 with GIP, and a milder version of retatrutide, which adds glucagon and GIP on top of GLP-1. Mazdutide's specific pairing — GLP-1 + glucagon — is shared only with survodutide among the well-known candidates.

What we do and don't know about the mechanism

The receptor pharmacology is well characterized, and the human trials confirm the mechanism translates into real weight and glucose changes in people.^[1][4] What is not yet established: long-term effects on hard clinical outcomes (heart attacks, strokes, liver-disease progression) have not been proven in an outcomes trial, and all mechanistic-to-clinical evidence comes from Chinese study populations, so how fully it generalizes to other groups is an open question.

How to read this section: for each benefit we give the plain-English claim, the mechanism behind it, the population actually studied, the size of the effect, and the limitation. Unlike most peptides on this site, mazdutide's evidence is genuine human trial data — but it is concentrated in Chinese populations and (for weight loss) capped at about 60 weeks of follow-up.

Weight loss (the headline benefit)

Claim: mazdutide produces substantial, dose-dependent body-weight loss. Mechanism: combined GLP-1 appetite suppression and glucagon-driven energy expenditure. Population & effect: the evidence builds across three trials:

• Phase 2 (obesity): in 248 Chinese adults with overweight or obesity tested at 3, 4.5, or 6 mg weekly over 24 weeks, the 6 mg dose produced -11.3% body weight versus +1.0% with placebo (n=61 vs 62) — a treatment difference of roughly 12 percentage points.^[3]
• Phase 3 GLORY-1 (pivotal, obesity): in 610 Chinese adults, mean weight loss at week 48 was ~14.0% with 6 mg and ~11% with 4 mg, versus a slight gain (~0.3%) with placebo (P<.001). Benefits were seen across all prespecified cardiometabolic measures. This trial was the basis for China's NMPA approval.^[1]
• Phase 3 GLORY-2 (higher dose): the 9 mg dose produced ~16.65% mean weight loss at week 60 versus 1.50% with placebo (n=307 vs 154), and 84.3% of the 9 mg group lost at least 5% of body weight versus 33.1% on placebo.^[2]

Limitation: all three trials were conducted in Chinese adults; there is no published pivotal trial in other populations, and the longest weight-loss follow-up is 60 weeks. There is no head-to-head trial against tirzepatide or semaglutide.

Blood-sugar control in type 2 diabetes

Claim: mazdutide meaningfully lowers HbA1c (a 3-month average blood-sugar measure) while also reducing weight. Mechanism: glucose-dependent insulin secretion and weight loss both improve glycemic control. Population & effect:

• Phase 2 (T2D): in Chinese patients with type 2 diabetes (3/4.5/6 mg mazdutide vs dulaglutide 1.5 mg vs placebo over 20 weeks), HbA1c fell by -1.41% to -1.67% with mazdutide versus +0.03% with placebo (all P<0.0001), with weight loss up to -7.1%.^[4]
• Phase 3 (T2D): at week 24, the 6 mg dose reduced HbA1c by -2.15% versus -0.14% with placebo, and body weight by -7.81% versus -1.26% (both P<0.0001).^[5]

Limitation: again, Chinese-only populations and relatively short (20–24 week) follow-up; long-term diabetes complication data are not available.

Liver fat and metabolic-liver disease (mechanistically promising)

Claim: the glucagon component may reduce liver fat directly. Mechanism: glucagon-receptor activation drives hepatic fat oxidation. Population & effect: this is mechanistically the most exciting differentiator from GLP-1-only drugs, and the weight-loss trials showed broad cardiometabolic improvement.^[1] Limitation: dedicated, published Phase 3 liver-histology outcomes for mazdutide (of the kind survodutide has generated in MASH) are not yet available, so treat the liver-fat benefit as strongly plausible and actively studied rather than as proven clinical outcome data.

The honest bottom line on benefits

• The weight-loss and glucose data are real and robust — this is not an animal-only compound.^[1][2]
• But the evidence is geographically narrow (Chinese populations) and time-limited (≤60 weeks for weight).
• No cardiovascular outcomes trial exists yet — we cannot yet say mazdutide reduces heart attacks or strokes the way semaglutide has been shown to.
• No head-to-head trials against tirzepatide or semaglutide have been published, so cross-drug comparisons are indirect.

Read this first: the dosing below comes directly from the published human trials — this is one of the few peptides on this site with genuine clinical dose data. However, mazdutide is approved only in China, and the material sold on the US research market is unregulated. Nothing here is medical advice or an endorsement of self-administration; it's a description of how the studied doses are structured.

Doses used in the published trials

Indication	Trial	Doses tested	Route / frequency	Duration
Obesity	Phase 2[3]	3 / 4.5 / 6 mg	SC, once weekly	24 weeks
Obesity	Phase 3 GLORY-1[1]	4 / 6 mg	SC, once weekly	48 weeks
Obesity	Phase 3 GLORY-2[2]	9 mg	SC, once weekly	60 weeks
Type 2 diabetes	Phase 2[4]	3 / 4.5 / 6 mg	SC, once weekly	20 weeks
Type 2 diabetes	Phase 3[5]	up to 6 mg	SC, once weekly	24 weeks

The 4 mg and 6 mg weekly doses are the ones China's NMPA approved. Phase 2 work established that doses below 3 mg/week are largely sub-therapeutic. GLORY-2 explored a higher 9 mg dose for greater weight loss, which is the basis of the supplementary application under NMPA review.^[1][2][6]

Dose escalation (why you don't start at the top)

Like all GLP-1-class drugs, mazdutide is started low and stepped up gradually so the gut can adapt — starting at a full therapeutic dose would cause severe nausea and vomiting. In the trials, patients began at a low weekly dose and escalated in roughly 4-week steps up to their target (for example, working up over several weeks to reach 6 mg). The practical principle: if a dose step isn't tolerated, hold at the current dose for a few extra weeks before stepping up again rather than pushing through. The 4 mg dose is a reasonable maintenance level for anyone who can't comfortably reach 6 mg. Escalation for mazdutide tends to be a touch slower than for semaglutide because the glucagon component adds to the gastrointestinal burden.

Reconstitution math, with a worked example

The clinical product is a pre-filled pen. Research-market vials, by contrast, arrive as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula is the same for any peptide:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: suppose a vial contains 20 mg of mazdutide and you add 1 mL of bacteriostatic water. That gives 20 ÷ 1 = 20 mg/mL. To draw a 4 mg dose: 4 ÷ 20 = 0.20 mL, which is 20 units on a standard 100-unit insulin syringe. A 6 mg dose is 6 ÷ 20 = 0.30 mL, or 30 units. If instead you added 2 mL of water to that same 20 mg vial, the concentration halves to 10 mg/mL, and a 6 mg dose becomes 0.60 mL (60 units).

Vial	BAC water	Concentration	4 mg dose	6 mg dose
20 mg	1 mL	20 mg/mL	0.20 mL (20 units)	0.30 mL (30 units)
20 mg	2 mL	10 mg/mL	0.40 mL (40 units)	0.60 mL (60 units)
10 mg	1 mL	10 mg/mL	0.40 mL (40 units)	0.60 mL (60 units)

Preparation basics: wipe the vial stopper with alcohol; inject the water slowly down the inside wall rather than onto the powder; swirl gently (never shake) until fully dissolved; then label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check your volumes, and the reconstitution guide for a full walkthrough.

Administration, timing, and missed doses

• Route: subcutaneous injection into the abdomen (at least 5 cm from the navel), thigh, or upper arm. Rotate sites weekly. See the injection guide.
• Timing: once weekly, any time of day, with or without food — but pick a consistent day each week to keep blood levels even.
• Missed dose: the general once-weekly rule is to take a missed dose promptly if it's within a few days of schedule, then resume the normal weekly day; if it's closer to the next scheduled dose, skip it. Never double up.

Cycle length and storage

• Duration: like the rest of the GLP-1 class, mazdutide is intended for continuous long-term use, not cycling — weight regain is expected after stopping. Trials ran 20–60 weeks.
• Storage: keep unopened material refrigerated at 2–8°C; protect from light; do not freeze. Once reconstituted, keep refrigerated and discard if the solution is cloudy or discolored. See the peptide storage guide.

Straight talk: mazdutide's side effects are predominantly gastrointestinal and typical of the GLP-1 drug class. They cluster during the dose-escalation phase, are mostly mild to moderate, and tend to ease as the body adapts. Because mazdutide has been through Phase 3 trials and a regulatory approval, its safety database is larger than most compounds discussed on this site — but there is still no long-term cardiovascular outcomes trial, and all data come from Chinese populations.^[1][4]

Reported side effects from the trials

The clearest frequency data come from the Phase 2 type 2 diabetes trial; the obesity trials show a similar GI-dominant pattern.^[4][1]

Effect	Frequency (active arms, Phase 2 T2D)	Notes
Diarrhea	~36%	Usually mild–moderate and transient
Decreased appetite	~29%	A pharmacological effect, not truly an "adverse" one
Nausea	~23%	Peaks during titration, declines with stable dosing
Vomiting	~14%	Dose-dependent
Hypoglycemia	~10% (vs 8% placebo)	Low-blood-sugar risk rises when combined with insulin or sulfonylureas

Across the program, gastrointestinal events peak during dose escalation and are mostly mild to moderate. No mazdutide-related deaths or unexpected serious safety signals were reported in the published trials, and the China NMPA approval reflects a favorable overall benefit–risk assessment in the studied population.^[1][6]

The glucagon-component considerations

The glucagon receptor activity is what differentiates mazdutide from pure GLP-1 drugs, and it carries a couple of class-specific watch points that reviewers apply to GLP-1/glucagon co-agonists generally:

• Modest heart-rate increase: glucagon-receptor agonists in this class tend to nudge resting heart rate up by a few beats per minute. New palpitations or exercise intolerance warrant medical evaluation.
• Liver enzymes: because the drug drives hepatic fat metabolism, transient changes in liver enzymes (ALT/AST) can occur; anyone with baseline liver concerns should have these monitored.
• Glucose handling: despite glucagon's blood-sugar-raising reputation, the concurrent GLP-1 activity kept glycemic control intact — and actually improved it — throughout the trials.^[4][5]

GLP-1 class risks that apply to mazdutide

• Pancreatitis: a class warning for all GLP-1-family drugs. Persistent severe abdominal pain (often radiating to the back) warrants stopping and evaluation.
• Thyroid C-cell tumors: rodent studies across the GLP-1 class showed C-cell tumors; a precautionary contraindication applies to anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
• Gallbladder events: rapid weight loss of any cause raises gallstone risk.
• Dehydration and kidney strain: usually secondary to severe nausea, vomiting, or diarrhea — stay hydrated during titration.

Who should avoid it

• Personal or family history of medullary thyroid carcinoma or MEN 2 (precautionary class contraindication)
• Pregnancy and breastfeeding — no adequate safety data; avoid
• Type 1 diabetes — not a substitute for insulin
• Active or recurrent pancreatitis, or severe gastrointestinal disease such as gastroparesis
• Severe liver or kidney impairment — data are limited

What to do if you experience side effects

• Mild GI symptoms during titration: hold at the current dose for a few extra weeks before escalating; eat smaller, lower-fat meals and hydrate.
• Severe, persistent abdominal pain: stop and get evaluated for pancreatitis.
• Persistent vomiting or signs of dehydration: pause dosing and restore fluids.
• New palpitations or reduced exercise tolerance: seek a cardiac check.

For broader context, see Are Peptides Safe? and Peptide Side Effects. A separate, real hazard with any research-market compound is product quality — covered next.

Why this section matters: there is a critical gap between the mazdutide studied in trials and the mazdutide sold online. The clinical drug is a manufactured, quality-controlled pen approved in China. The material in US "research peptide" markets is unregulated, and its purity, dose accuracy, and even identity cannot be assumed without independent lab testing. For an unapproved compound, contamination and mislabeling can be a bigger practical risk than the peptide itself.

What a credible product should show

• Third-party Certificate of Analysis (COA): independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirmation, tied to the specific lot you're buying.
• Endotoxin (LAL) testing: essential for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial — not a pre-mixed "ready to use" liquid.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed liquid peptide (shorter shelf life, higher contamination risk)
• Prices far below the market
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

• Approved in China, not the US: China's NMPA approved mazdutide on June 27, 2025 for chronic weight management (4 mg and 6 mg doses) — the first GLP-1/glucagon dual agonist approved anywhere. A 9 mg supplementary application is under NMPA review.^[6]
• Not FDA-approved: mazdutide has no US marketing approval, and US Phase 3 development is at an earlier stage than the Chinese program.^[6]
• Research-market material is unregulated: mazdutide sold in US "research peptide" channels is not the clinical-grade molecule from the Innovent/Lilly trials, and its quality cannot be verified without testing.

For the complete legal picture, read Are Peptides Legal?

Mazdutide is one of several multi-target, GLP-1-based metabolic drugs. None of the comparisons below are backed by published head-to-head human trials — they contrast the receptor strategy and each drug's own trial results. For the full class picture, see the complete GLP-1 guide.

Compound	Receptor targets	Peak weight loss (own trials)	Status
Mazdutide	GLP-1 + glucagon	~14% (6 mg, 48 wk); ~16.6% (9 mg, 60 wk)	Approved in China (NMPA), not FDA
Survodutide	GLP-1 + glucagon	~18.7% (Phase 2)	Investigational; FDA Breakthrough for MASH
Retatrutide	GLP-1 + GIP + glucagon	up to ~24% (Phase 2)	Investigational (Phase 3 ongoing)
Tirzepatide	GLP-1 + GIP	up to ~22.5% (SURMOUNT-1)	FDA-approved (Mounjaro/Zepbound)
Semaglutide	GLP-1 only	~14.9% (STEP-1)	FDA-approved (Ozempic/Wegovy)

Mazdutide vs. survodutide: these are the two GLP-1/glucagon dual agonists. Survodutide's Phase 2 weight loss looks numerically higher, but mazdutide has the larger regulatory and human-exposure track record thanks to its China approval and completed Phase 3 program.

Mazdutide vs. tirzepatide: both are dual agonists, but tirzepatide's second target is GIP, not glucagon. Tirzepatide's reported weight loss is higher, while mazdutide's glucagon component adds direct liver-fat activity that GIP-based drugs don't share. Tirzepatide is FDA-approved; mazdutide is not.